Rheumatologic complications of CAR-T Cell therapy. Experience of a single center DOI
José A. Gómez‐Puerta,

Ana Monegal,

Andrés Ponce

et al.

Seminars in Arthritis and Rheumatism, Journal Year: 2024, Volume and Issue: 71, P. 152610 - 152610

Published: Dec. 27, 2024

Language: Английский

Mobilizing CARs: Benefits, Drawbacks, and Directions for Outpatient CAR T-cell therapy DOI

Jennifer S. Woo,

Kim-Anh Nguyen, Lawrence Liu

et al.

Seminars in Hematology, Journal Year: 2024, Volume and Issue: 61(5), P. 273 - 283

Published: Aug. 23, 2024

Language: Английский

Citations

2
CYTOKINE RELEASE SYNDROME IN ONCOLOGIC PATIENTS TREATED WITH CAR-T DOI Creative Commons

Michel Bolis

Published: Aug. 26, 2024

Background: The development and use of immunotherapy, particularly chimeric antigen receptor T cells (CAR-T), has transformed cancer treatment. However, managing related toxicities remains a significant challenge. Objectives: To provide an overview cytokine release syndrome (CRS) in patients receiving CAR-T treatment, focusing on its clinical therapeutic management. Methods: A literature review was conducted to gather current knowledge insights CRS associated with therapy. Sources included peer-reviewed journals, studies, expert reviews. Results: Prevalence CRS: is common toxicity therapy, variable incidence depending the type product used patient-specific factors. Clinical Presentation: can range from mild flu-like symptoms severe, life-threatening manifestations, including high fever, hypotension, multi-organ dysfunction. Challenges Identification: Differentiating other conditions such as sepsis challenging due overlapping features. Therapeutic Management: Management strategies include supportive care, corticosteroids, inhibitors like tocilizumab. Early recognition intervention are critical improve patient outcomes. Conclusion: Effective management cell therapy vital mitigate potentially fatal consequences. Continued research vigilance essential for improving safety efficacy treatments patients.

Language: Английский

Citations

0
Celebrating a year of immunotherapy/cell and gene therapy in Blood Advances DOI Creative Commons
Catherine M. Bollard, Andrew S. Weyrich

Blood Advances, Journal Year: 2024, Volume and Issue: 8(24), P. 6334 - 6336

Published: Dec. 24, 2024

Language: Английский

Citations

0
Rheumatologic complications of CAR-T Cell therapy. Experience of a single center DOI
José A. Gómez‐Puerta,

Ana Monegal,

Andrés Ponce

et al.

Seminars in Arthritis and Rheumatism, Journal Year: 2024, Volume and Issue: 71, P. 152610 - 152610

Published: Dec. 27, 2024

Language: Английский

Citations

0